| 149.145 0.745 (0.5%) | 10-15 12:17 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 178.72 | 1-year : | 208.75 |
| Resists | First : | 153.02 | Second : | 178.72 |
| Pivot price | 142.09  |
|||
| Supports | First : | 128.12 | Second : | 112.73 |
| MAs | MA(5) : | 147.96  |
MA(20) : | 137.62 |
| MA(100) : | 125.05 |
MA(250) : | 136.74 |
|
| MACD | MACD : | 7.2 |
Signal : | 6.5 |
| %K %D | K(14,3) : | 86 |
D(3) : | 83.8 |
| RSI | RSI(14): 65.2 |
|||
| 52-week | High : | 182.52 | Low : | 102.97 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RGEN ] has closed below upper band by 33.4%. Bollinger Bands are 104.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 151.04 - 151.78 | 151.78 - 152.5 |
| Low: | 143.37 - 144.28 | 144.28 - 145.17 |
| Close: | 146.69 - 148.15 | 148.15 - 149.6 |
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Wed, 15 Oct 2025
Repligen Corporation to Announce Third Quarter 2025 Financial Results on October 28 - Quiver Quantitative
Wed, 15 Oct 2025
Repligen to Report Third Quarter 2025 Financial Results - MarketScreener
Wed, 15 Oct 2025
Oct 28 Webcast: Repligen to Report Third Quarter Results; Conference Call 8:30 a.m. ET - Stock Titan
Mon, 13 Oct 2025
Repligen (RGEN): Exploring Valuation as Regulatory Clarity Fuels New Growth Optimism - simplywall.st
Mon, 13 Oct 2025
Repligen Corporation (RGEN) Stock Analysis: An Investor’s Guide to a 23.4% Potential Upside - DirectorsTalk Interviews
Sun, 12 Oct 2025
The Bull Case For Repligen (RGEN) Could Change Following Drug Pricing Clarity and Bioprocessing Demand Shift - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 56 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 6.3 (%) |
| Held by Institutions | 99.8 (%) |
| Shares Short | 3,410 (K) |
| Shares Short P.Month | 3,620 (K) |
| EPS | -0.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 36.65 |
| Profit Margin | -2.1 % |
| Operating Margin | 5.2 % |
| Return on Assets (ttm) | 1.1 % |
| Return on Equity (ttm) | -0.7 % |
| Qtrly Rev. Growth | 14.8 % |
| Gross Profit (p.s.) | 6.1 |
| Sales Per Share | 11.97 |
| EBITDA (p.s.) | 2.24 |
| Qtrly Earnings Growth | 160 % |
| Operating Cash Flow | 132 (M) |
| Levered Free Cash Flow | 155 (M) |
| PE Ratio | -594.8 |
| PEG Ratio | 0 |
| Price to Book value | 4.05 |
| Price to Sales | 12.41 |
| Price to Cash Flow | 63.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|